HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eric Raymond Selected Research

irofulven

10/2007A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
7/2006A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
4/2006Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
8/2004Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
5/2004Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
11/2003Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
7/2003Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Eric Raymond Research Topics

Disease

98Neoplasms (Cancer)
01/2022 - 08/2002
19Hepatocellular Carcinoma (Hepatoma)
01/2022 - 01/2009
19Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2021 - 12/2009
11Renal Cell Carcinoma (Grawitz Tumor)
06/2016 - 01/2006
8Carcinoma (Carcinomatosis)
01/2016 - 01/2002
8Neoplasm Metastasis (Metastasis)
03/2014 - 01/2009
7Diarrhea
01/2021 - 11/2005
6Breast Neoplasms (Breast Cancer)
07/2021 - 08/2005
6Asthenia
01/2021 - 11/2005
6Carcinogenesis
09/2015 - 08/2010
6Prostatic Neoplasms (Prostate Cancer)
09/2014 - 07/2003
5Hypertension (High Blood Pressure)
07/2021 - 06/2007
5Fatigue
01/2021 - 01/2009
5Neutropenia
01/2019 - 06/2005
5Primitive Neuroectodermal Tumors (PNET)
01/2018 - 10/2011
5Squamous Cell Carcinoma of Head and Neck
11/2017 - 07/2004
5Colonic Neoplasms (Colon Cancer)
05/2010 - 08/2002
4Head and Neck Neoplasms (Head and Neck Cancer)
01/2019 - 04/2005
4Pancreatic Neoplasms (Pancreatic Cancer)
10/2018 - 04/2009
4Disease Progression
12/2016 - 06/2007
4Glioma (Gliomas)
06/2009 - 07/2003
3Cholangiocarcinoma
01/2022 - 04/2015
3Liver Neoplasms (Liver Cancer)
01/2022 - 11/2013
3Melanoma (Melanoma, Malignant)
01/2021 - 08/2007
3Adenocarcinoma
11/2015 - 08/2005
3Necrosis
04/2015 - 10/2007
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
12/2014 - 06/2007
3Glioblastoma (Glioblastoma Multiforme)
12/2013 - 07/2007
3Hand-Foot Syndrome
11/2013 - 01/2011
3Thrombocytopenia (Thrombopenia)
11/2013 - 05/2004
3Colorectal Neoplasms (Colorectal Cancer)
05/2013 - 08/2005
3Kidney Neoplasms (Kidney Cancer)
02/2012 - 06/2004
2Edema (Dropsy)
01/2021 - 12/2015
2Leukemia
12/2019 - 07/2003
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2011 - 06/2003

Drug/Important Bio-Agent (IBA)

34Sunitinib (Sutent)FDA Link
01/2021 - 01/2006
13Pharmaceutical PreparationsIBA
01/2022 - 06/2004
13EverolimusFDA Link
06/2016 - 04/2008
12Sorafenib (BAY 43-9006)FDA Link
08/2021 - 01/2009
11Phosphotransferases (Kinase)IBA
01/2022 - 08/2006
10TOR Serine-Threonine KinasesIBA
04/2015 - 06/2004
9Biomarkers (Surrogate Marker)IBA
01/2020 - 07/2011
9GemcitabineFDA Link
10/2018 - 07/2010
8Tyrosine Kinase InhibitorsIBA
12/2014 - 06/2003
7Irinotecan (Camptosar)FDA LinkGeneric
01/2016 - 08/2002
7Imatinib Mesylate (Gleevec)FDA Link
12/2014 - 09/2005
7Antineoplastic Agents (Antineoplastics)IBA
09/2014 - 08/2006
7irofulvenIBA
10/2007 - 07/2003
6Sirolimus (Rapamycin)FDA Link
01/2022 - 01/2006
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2012 - 01/2009
5Hormones (Hormone)IBA
07/2021 - 08/2004
5Cytotoxins (Cytolysins)IBA
05/2015 - 11/2007
5Proteins (Proteins, Gene)FDA Link
12/2013 - 08/2004
5temsirolimusFDA Link
05/2013 - 06/2004
5MTOR InhibitorsIBA
05/2013 - 01/2006
5Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
06/2012 - 08/2005
5Fluorouracil (Carac)FDA LinkGeneric
09/2011 - 08/2002
5Cisplatin (Platino)FDA LinkGeneric
09/2011 - 07/2003
4LY-2157299IBA
01/2021 - 08/2015
4Transforming Growth Factor beta (TGF-beta)IBA
01/2020 - 05/2010
4PlatinumIBA
09/2016 - 03/2008
4Oxaliplatin (Eloxatin)FDA LinkGeneric
04/2015 - 08/2002
4Messenger RNA (mRNA)IBA
12/2013 - 05/2010
4Angiogenesis InhibitorsIBA
09/2012 - 10/2007
4Protein Kinase CIBA
05/2010 - 08/2006
3tepotinibIBA
08/2021 - 01/2018
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 06/2013
3N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA
01/2021 - 10/2018
3LigandsIBA
11/2017 - 12/2012
3Monoclonal AntibodiesIBA
01/2015 - 08/2007
3Galectin 1 (LGALS1)IBA
09/2014 - 06/2012
3ErbB Receptors (EGF Receptor)IBA
03/2014 - 06/2003
3VimentinIBA
12/2012 - 05/2010
3tyrosine receptor (receptor, tyrosine)IBA
10/2011 - 08/2006
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2011 - 08/2006
2Cyclin D1IBA
01/2022 - 06/2011
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2021 - 02/2014
2Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
01/2021 - 08/2006
2OTX015IBA
12/2019 - 12/2016
2BilirubinIBA
01/2019 - 11/2002
2antineoplaston A10 (A 10)IBA
01/2018 - 07/2011
2Transaminases (Aminotransferases)IBA
12/2015 - 11/2005
2Docetaxel (Taxotere)FDA Link
09/2014 - 01/2013
2compound 0118IBA
09/2014 - 06/2012
2Carboplatin (JM8)FDA LinkGeneric
06/2014 - 07/2008
2elisidepsinIBA
06/2014 - 03/2013
2ChemokinesIBA
01/2014 - 12/2013
2calix(4)areneIBA
10/2013 - 06/2012
2Peptides (Polypeptides)IBA
10/2013 - 08/2007
2thiamine triphosphorate (TTP)IBA
09/2012 - 07/2011
2Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2012 - 01/2009
2Paclitaxel (Taxol)FDA LinkGeneric
09/2011 - 07/2008
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
06/2011 - 04/2008

Therapy/Procedure

41Therapeutics
07/2021 - 06/2003
13Drug Therapy (Chemotherapy)
09/2016 - 08/2002
3Drug Tapering
09/2014 - 03/2007
3Radiotherapy
10/2008 - 07/2007
2Aftercare (After-Treatment)
04/2015 - 06/2009
2Castration
09/2014 - 01/2013
2Induction Chemotherapy
03/2013 - 04/2005